FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2557403778> ?p ?o ?g. }

• W2557403778 endingPage "926" @default.
• W2557403778 startingPage "926" @default.
• W2557403778 abstract "Abstract Protein disulfide isomerase (PDI) is a widely expressed oxidoreductase that catalyzes the rearrangement of intramolecular disulfide bonds during protein maturation in the endoplasmic reticulum. However, PDI can also be secreted from both platelets and endothelial cells during thrombus formation. Inhibition of extracellular PDI in the vasculature using neutralizing antibodies or bacitracin blocks thrombus formation in pre-clinical studies. Our previous experiments identified quercetin-3-rutinoside as an inhibitor of PDI and a potent antithrombotic. Recently, we performed a high-throughput screen of the MLSMR library through the Molecular Libraries Probe Production Centers Network (MLPCN) to identify more potent and selective inhibitors of PDI. We now compare the activity of the most potent lead, ML359, to previously described PDI inhibitors and assess its antithrombotic activity. ML359 inhibited the reductase activity of PDI in the insulin turbidometric assay with an IC50 of 0.3-0.6 microM. By comparison, quercetin-3-rutinoside and juniferdin inhibited PDI with IC50s of 6-10 microM, while bacitracin inhibited PDI reductase activity with an IC50 of 100 microM. ML359 demonstrated no confirmed activity at <10 microM in any of the other of 380 biological assays in which it has been tested within the MLPCN. Additionally, ML359 was selective for PDI, failing to inhibit ERp5, ERp57, ERP72, thioredoxin or thioredoxin reductase activity. Inhibition of PDI by the ML359 was entirely reversible and it did not demonstrate toxicity in a HeLa cell assay. In preparation for pre-clinical studies, further evaluation of the biophysical properties of ML359 was performed. ML359 demonstrated acceptable solubility in PBS, human plasma and GSH. However, it showed poor stability in mouse plasma as well as in presence of liver microsomes. To optimize and improve these biophysical properties of the ML359, over 85 analogs of the lead were synthesized. Modulation of the ethyl substituent of the ester group with bulky isopropyl or t-butyl substituents increased the mouse plasma stability from ∼5% in ML359 to ∼75% and ∼95% in the analogs, respectively. These substitutions only minimally altered the potency of the compound (0.6-0.9 microM). The ML359 analogs demonstrated increased inhibitory activity in platelet aggregation assays, with inhibition at 30 microM increasing from 25% for ML359 to 97 and 100% for the isopropyl and t-butyl substituted analogs, respectively. The ability of ML359 to prevent thrombus formation in a laser injury mouse model was examined. Thrombus formation was monitored following laser injury of cremaster arterioles and the effect of ML359 infusion on platelet accumulation evaluated. ML359 exposure resulted in a significantly smaller thrombus that that observed in the animals infused with vehicle alone. ML359 and its active analogs have enhanced properties compared to the first generation PDI antagonists. These compounds are substantially more potent than previously described PDI inhibitors such as bacitracin and show significant potential as second generation inhibitors to probe PDI function in biological systems. ML359 analogs could ultimately be developed as antithrombotics that target PDI. Disclosures: No relevant conflicts of interest to declare." @default.
• W2557403778 created "2016-12-08" @default.
• W2557403778 creator A5005122246 @default.
• W2557403778 creator A5006713516 @default.
• W2557403778 creator A5010599330 @default.
• W2557403778 creator A5020578245 @default.
• W2557403778 creator A5020637799 @default.
• W2557403778 creator A5020703207 @default.
• W2557403778 creator A5026633318 @default.
• W2557403778 creator A5028221234 @default.
• W2557403778 creator A5043112684 @default.
• W2557403778 creator A5052833606 @default.
• W2557403778 creator A5055466396 @default.
• W2557403778 creator A5066721777 @default.
• W2557403778 creator A5086104008 @default.
• W2557403778 date "2013-11-15" @default.
• W2557403778 modified "2023-10-14" @default.
• W2557403778 title "Development Of Second Generation Thiol Isomerase Inhibitors To Prevent Thrombus Formation" @default.
• W2557403778 doi "https://doi.org/10.1182/blood.v122.21.926.926" @default.
• W2557403778 hasPublicationYear "2013" @default.
• W2557403778 type Work @default.
• W2557403778 sameAs 2557403778 @default.
• W2557403778 citedByCount "3" @default.
• W2557403778 countsByYear W25574037782015 @default.
• W2557403778 countsByYear W25574037782020 @default.
• W2557403778 countsByYear W25574037782023 @default.
• W2557403778 crossrefType "journal-article" @default.
• W2557403778 hasAuthorship W2557403778A5005122246 @default.
• W2557403778 hasAuthorship W2557403778A5006713516 @default.
• W2557403778 hasAuthorship W2557403778A5010599330 @default.
• W2557403778 hasAuthorship W2557403778A5020578245 @default.
• W2557403778 hasAuthorship W2557403778A5020637799 @default.
• W2557403778 hasAuthorship W2557403778A5020703207 @default.
• W2557403778 hasAuthorship W2557403778A5026633318 @default.
• W2557403778 hasAuthorship W2557403778A5028221234 @default.
• W2557403778 hasAuthorship W2557403778A5043112684 @default.
• W2557403778 hasAuthorship W2557403778A5052833606 @default.
• W2557403778 hasAuthorship W2557403778A5055466396 @default.
• W2557403778 hasAuthorship W2557403778A5066721777 @default.
• W2557403778 hasAuthorship W2557403778A5086104008 @default.
• W2557403778 hasConcept C158617107 @default.
• W2557403778 hasConcept C181199279 @default.
• W2557403778 hasConcept C185592680 @default.
• W2557403778 hasConcept C2776980637 @default.
• W2557403778 hasConcept C2777737464 @default.
• W2557403778 hasConcept C3623737 @default.
• W2557403778 hasConcept C5098756 @default.
• W2557403778 hasConcept C55493867 @default.
• W2557403778 hasConceptScore W2557403778C158617107 @default.
• W2557403778 hasConceptScore W2557403778C181199279 @default.
• W2557403778 hasConceptScore W2557403778C185592680 @default.
• W2557403778 hasConceptScore W2557403778C2776980637 @default.
• W2557403778 hasConceptScore W2557403778C2777737464 @default.
• W2557403778 hasConceptScore W2557403778C3623737 @default.
• W2557403778 hasConceptScore W2557403778C5098756 @default.
• W2557403778 hasConceptScore W2557403778C55493867 @default.
• W2557403778 hasIssue "21" @default.
• W2557403778 hasLocation W25574037781 @default.
• W2557403778 hasOpenAccess W2557403778 @default.
• W2557403778 hasPrimaryLocation W25574037781 @default.
• W2557403778 hasRelatedWork W1989914560 @default.
• W2557403778 hasRelatedWork W2049132071 @default.
• W2557403778 hasRelatedWork W2061986421 @default.
• W2557403778 hasRelatedWork W2066053439 @default.
• W2557403778 hasRelatedWork W2086054419 @default.
• W2557403778 hasRelatedWork W2253688861 @default.
• W2557403778 hasRelatedWork W2406109416 @default.
• W2557403778 hasRelatedWork W2533459914 @default.
• W2557403778 hasRelatedWork W2742343623 @default.
• W2557403778 hasRelatedWork W2960732954 @default.
• W2557403778 hasVolume "122" @default.
• W2557403778 isParatext "false" @default.
• W2557403778 isRetracted "false" @default.
• W2557403778 magId "2557403778" @default.
• W2557403778 workType "article" @default.